Plain-English translation of NCT02143986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a blood protein called glycosylated ferritin to see if it can help doctors quickly identify rare immune diseases, particularly adult-onset Still's disease and a condition called macrophagic activation syndrome. Right now, these diseases are hard to diagnose because they share symptoms with other serious conditions like sepsis and infections. This study will compare ferritin levels in patients with suspected immune diseases to those with other serious conditions to see if the medication can reliably tell them apart.
These rare immune diseases can be life-threatening, but they're often confused with infections or other conditions, leading to delays in proper treatment. A better diagnostic test could help doctors identify and treat these diseases faster, potentially improving patient outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will donate a blood sample, which doctors will test for the glycosylated ferritin marker and other blood markers related to immune activation. Researchers will also review your medical history and clinical symptoms to understand your diagnosis better. The study is observational, meaning you won't receive any new treatment — researchers are simply analyzing your blood to improve diagnostic methods.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Belgium